Myocarditis data from Korea
June 17, 2023
373,006
21,357
4,947
7.05%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around June 17, 2023
See what was published immediately before and after this episode.
11:56Now PlayingMyocarditis data from Korea
YouTube Description
as posted by the channel19.8% of total VRM was severe
COVID-19 vaccination-related myocarditis: a Korean nationwide study
Nationwide study,
incidence and outcomes of COVID-19 vaccination-related myocarditis (VRM).
44, 276, 704 individuals, at least 1 dose
Incidence and clinical courses of VRM cases
Diagnosis confirmed by Expert Adjudication Committee of the Korea Disease Control and Prevention Agency
COVID-19 VRM
1, 533 presumptive cases
Confirmed in 480 cases
(1.08 cases per 100 000 persons)
Incidence was significantly higher in men
Men, 1.35 per 100 000 persons
Women, 0.82 per 100 000 persons
Males aged 12 to 17, 5.29 cases per 100 000 persons
Females over 70, 0.16 cases per 100 000 persons
CDC today
COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19.
Mostly after first or second dose
mRNA vaccines compared to other vaccines
VRM after mRNA vaccines, 1.46 per 100 000 persons
VRM after AZ vaccine, 0.14 per 100 000 persons
P les than 0.001
Denmark, VRM
BNT162b2, 1.4 per 100 000 vaccinated individuals
mRNA-1273, 4.2 per 100 000
(within 28 days of vaccination)
Severe VRM was identified in 95 cases
19.8% of total VRM
(0.22 per 100 000 vaccinated persons)
85 intensive care unit admission
(17.7% of total VRM)
36 cases of fulminant myocarditis
7.5% of total VRM
21 cases required extracorporeal membrane oxygenation
(4.4% of total VRM)
21 more severe adverse events
(4.4% of total VRM)
Eight out of 21 were sudden cardiac dea*** (SCD)
(attributable to VRM proved by an autopsy)
All cases of SCD attributable to VRM were aged under 45 years and received mRNA vaccines
1 heart transplantation
Conclusion
Moreover, SCD should be closely monitored as a potentially fat** complication of COVID-19 vaccination.
Most common presenting symptom
Chest pain or discomfort
Median time from the vaccination to symptom onset, 3 days
(IQR, 1–10 days)
COVID-19 VRM incidence was highest in mRNA-1273 vaccine (Moderna)
Followed by BNT162b2
J and J Ad26 0.20 per 100 000 persons
AZ ChAdOx1 0.14 per 100 000 persons
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.